Recombinant human granulocyte colony-stimulating factor (filgrastim) following high-dose chemotherapy and peripheral blood progenitor cell rescue in high-grade non-Hodgkin's lymphoma: clinical benefits at no extra cost.

In order to evaluate the potential clinical and economic benefits of granulocyte colony-stimulating factor (G-CSF, filgrastim) following peripheral blood progenitor cells (PBPC) rescue after high-dose chemotherapy (HDCT), 23 consecutive patients aged less than 60 years with poor-prognosis, high-grad...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, S. M., Radford, J. A., Dobson, L., Huq, T., Ryder, W. D., Pettengell, R., Morgenstern, G. R., Scarffe, J. H., Crowther, D.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150159/
https://www.ncbi.nlm.nih.gov/pubmed/9579836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150159/
https://www.ncbi.nlm.nih.gov/pubmed/9579836

Ejemplares similares